ISSN: 1741-1343
Journal Home
Journal Guideline
Journal of Generic Medicines Q4 Unclaimed
Journal of Generic Medicines is a journal indexed in SJR in Pharmaceutical Science with an H index of 14. It has a best quartile of Q4. It is published in English.
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy:
Type of publications:
Publication frecuency: -
- €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
-
SJR Impact factor14
H Index0
Total Docs (Last Year)30
Total Docs (3 years)0
Total Refs5
Total Cites (3 years)24
Citable Docs (3 years)21
Cites/Doc (2 years)0.0
Ref/DocOther journals with similar parameters
Iranian Journal of Pharmaceutical Sciences Q4
Thai Journal of Pharmaceutical Sciences Q4
BioPharm International Q4
Bulletin of Pharmaceutical Sciences Q4
U.S. Pharmacist Q4
Compare this journals
Aims and Scope
Best articles by citations
Data protection: The new IP Frontier - An overview of existing laws and regulations
View moreDeveloping a legislative pathway for biosimilars in the United States
View moreSuitability petitions and Pediatric Research Equity Act evaluation - Basic understanding and recent case studies
View moreTendering short-term pricing policies and the impact on patients, governments and the sustainability of the generic medicines industry
View moreWinds of change are blowing for diagnostic methods patents
View moreWould the Trans-Pacific Partnership Agreement undermine Japan's efforts to control health care expenditures?
View moreEditorial
View morePreliminary injunctions in pharmaceutical cases
View morePreliminary injunctions, regulatory approvals and parallel imports
View moreEU Case Reports
View morePost PLIVA v. Mensing liability for generic medicine manufacturers: Food and Drug Administration to propose rule changes creating parity between generic and brand-name medicine manufacturers
View moreA survey assessing knowledge and perception of prescribers towards generic medicines in Hospital Seberang Jaya
View moreThe 'Single Place of Truth': Effective regulatory information management for Generics
View moreDoes the patent office really believe delay occurs before it actually occurs? The effect of Wyeth et al v. Dudas on patent term adjustments
View moreThe impact of Indonesian generic medicine pricing policy on medicine prices
View morePracticalities of paediatric extensions to the Supplementary Protection Certificate
View moreThe SPC manufacturing waiver: Good for patients, good for jobs, good for Europe
View moreWhat is obvious?
View moreBiological generics: A business case
View moreIndian API industry has the tide turned?
View moreJordanian stakeholder attitudes toward generic substitution
View moreWhat is the value of authorised generic agreements? Assessments on the French market
View moreSunovion v. Teva and Reddy: Reddy's promise not to infringe was insufficient to avoid infringement
View moreAll costs, no benefits: How the US-Jordan free trade agreement affects access to medicines
View more
Comments